Skip to content

Effect of Neuromuscular Blockade and Reversal on Breathing

Effect of Neuromuscular Blockade and Reversal by Sugammadex Versus Neostigmine on Breathing When Hypoxic or Hypercapnic in Volunteers

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02845375
Acronym
BREATH
Enrollment
46
Registered
2016-07-27
Start date
2016-09-01
Completion date
2018-09-01
Last updated
2020-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Insufficiency

Brief summary

In this study the investigators will assess (i) the effect of partial neuromuscular blockade (NMB; TOF ratio 0.8 and 0.6) induced by low-dose rocuronium on the ventilatory response to isocapnic hypoxia and (ii) the effect over time (from TOF 0.6 to TOF 1.0) of the reversal by sugammadex, neostigmine or placebo in healthy volunteers. Additionally the investigators will assess the effect of partial NMB (TOF ratio 0.6) induced by low-dose rocuronium on the ventilatory response to hypercapnia and effect over time (from TOF 0.6 to TOF 1.0) of the reversal by sugammadex, neostigmine or placebo in healthy volunteers.

Detailed description

The carotid bodies, located at the bifurcation of the common carotid artery, play a crucial and life-saving role in the control of breathing in humans. The carotid bodies contain type 1 cells that are primarily sensitive to low oxygen concentrations in arterial blood. In response to low oxygen the carotid bodies send information to the brainstem respiratory centers and a brisk hyperventilatory response will be initiated ensuring an increase in uptake of oxygen via the lungs. Following surgery, a rapid return of the carotid body function is vital and persistent loss of carotid body function may result in respiratory complications that occur independent of the effects of anesthetics (incl. muscle relaxants) on respiratory muscles. Respiratory complications that are related to the loss of carotid body function include the inability to respond properly to hypoxia as well the inability to overcome upper airway obstruction. The latter is especially important in patients with sleep disordered-breathing and obese patients. These patients rely on the optimal function of their carotid bodies in response to hypoxia or upper airway closure. Important neurotransmitters involved in the carotid body response to hypoxia include acetylcholine, which acts through local nicotinergic acetylcholine receptors. Apart from the observation that muscle relaxants (which are blockers of the acetylcholine receptors) affect the proper functioning of the carotid bodies, the investigators have no knowledge on the dynamic effects of muscle relaxants on carotid body function over time or on the relationship between carotid body function and Train-of-Four (TOF) ratio over time. Additionally, there is no data on the link between the use of NMB antagonists and return of carotid body function. Linking TOF ratio to carotid body function is of clinical importance as a possible relationship will allow clinicians to predict carotid body function from the TOF ratio. The latter is highly relevant as the investigators show in a previous trial that a large proportion of patients is extubated at TOF ratio's \< 0.7. Apart from the carotid bodies, chemoreceptors in the brainstem exist that are sensitive to hypercapnia. This response system is not under control of cholinergic neurotransmission. Since the investigators may assume that the hypercapnic ventilatory response is not influenced by muscle relaxants the investigators can use this response to calibrate the hypoxic ventilatory response as both responses are equally affected by the effect of muscle relaxants on muscle function. As stated there is data on the effect of muscle relaxants on carotid body function at one fixed TOF ratio (TOF ratio fixed at 0.7). No data are available on: 1. Dynamic effect of carotid body function as measured by the hypoxic ventilatory response at TOF ratio's slowly changing from 0.6 to 1.0; 2. Dynamic effect of reversal of NMB by sugammadex versus neostigmine. Sugammadex and neostigmine are both reversal agents of neuromuscular blockade. At their institution the investigators use both agents in clinical practice but remain without knowledge on their effects on carotid body function. The current proposal is designed to study items 1 and 2 in healthy awake volunteers.

Interventions

DRUGSugammadex

Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.

DRUGNeostigmine

Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.

DRUGPlacebo

Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.

Sponsors

Leiden University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* male gender * age 18 years and older * body mass index \< 30 kg/m2.

Exclusion criteria

* Known or suspected neuromuscular disorders impairing neuromuscular function; * allergies to muscle relaxants, anesthetics or narcotics; * a (family) history of malignant hyperthermia or any other muscle disease; * any medical, neurological or psychiatric illness (including a history of anxiety).

Design outcomes

Primary

MeasureTime frameDescription
Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)during the 1-2 hours following reversalThe change in breathing response to a decrease in inspired oxygen concentration, which equals the isocapnic ventilatory response to hypoxia.

Countries

Netherlands

Participant flow

Recruitment details

46 subjects were enrolled.6 did not meet inclusion citeria. 40 subjects were randomized

Participants by arm

ArmCount
PLACEBO
Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained. Placebo: Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
12
NEOSTIGMINE
intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained. Neostigmine: Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
12
SUGAMMADEX
intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained. Sugammadex: Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
12
Total36

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall Studyupper airway obstruction121

Baseline characteristics

CharacteristicNEOSTIGMINEPLACEBOSUGAMMADEXTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
12 Participants12 Participants12 Participants36 Participants
Age, Continuous23 years20 years23 years22 years
Breathing response to a reduction in inspired oxygen concentration (hypoxic ventilatory response)0.43 L/min/% oxygen saturation
STANDARD_DEVIATION 0.23
0.66 L/min/% oxygen saturation
STANDARD_DEVIATION 0.21
0.54 L/min/% oxygen saturation
STANDARD_DEVIATION 0.16
0.55 L/min/% oxygen saturation
STANDARD_DEVIATION 0.22
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
12 Participants12 Participants12 Participants36 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Region of Enrollment
Netherlands
12 participants12 participants12 participants36 participants
Sex: Female, Male
Sex
Female
0 Participants0 Participants0 Participants0 Participants
Sex: Female, Male
Sex
Male
12 Participants12 Participants12 Participants36 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 120 / 120 / 12
other
Total, other adverse events
0 / 120 / 120 / 12
serious
Total, serious adverse events
0 / 120 / 120 / 12

Outcome results

Primary

Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)

The change in breathing response to a decrease in inspired oxygen concentration, which equals the isocapnic ventilatory response to hypoxia.

Time frame: during the 1-2 hours following reversal

Population: Healthy male volunteers

ArmMeasureGroupValue (MEAN)Dispersion
PLACEBOBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)Relaxation0.34 L/min/% desaturationStandard Deviation 0.22
PLACEBOBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)Baseline0.66 L/min/% desaturationStandard Deviation 0.21
PLACEBOBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)Reversal0.49 L/min/% desaturationStandard Deviation 0.13
NEOSTIGMINEBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)Relaxation0.29 L/min/% desaturationStandard Deviation 0.22
NEOSTIGMINEBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)Baseline0.43 L/min/% desaturationStandard Deviation 0.22
NEOSTIGMINEBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)Reversal0.36 L/min/% desaturationStandard Deviation 0.2
SUGAMMADEXBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)Baseline0.54 L/min/% desaturationStandard Deviation 0.16
SUGAMMADEXBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)Reversal0.31 L/min/% desaturationStandard Deviation 0.17
SUGAMMADEXBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)Relaxation0.31 L/min/% desaturationStandard Deviation 0.17
Primary

Breathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)

The ventilatory response to a decrease in oxygen saturaytion of 80%

Time frame: 0-10 minutes following reversal

Population: The ventilation-saturation data were analyzed using linear regreassion analysis. The slope is the acute hypoxic ventilatory response.

ArmMeasureValue (MEAN)Dispersion
PLACEBOBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)0.49 L/min/%Standard Deviation 0.13
NEOSTIGMINEBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)0.36 L/min/%Standard Deviation 0.2
SUGAMMADEXBreathing Increase Due to a Reduction in Inspired Oxygen Saturation (Hypoxic Ventilatory Response)0.48 L/min/%Standard Deviation 0.13
p-value: 0.299ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026